tezosentan

structure in first source

Also Known As:

5-isopropyl-pyridine-2-sulfonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl--pyridin-4-yl)--pyrimidin-4-ylamide; RO 61-0612; RO 610612; 2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(2H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)-

Networked: 93 relevant articles (13 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - tezosentan: 93
  - Pyridines: 88
    - tezosentan: 93

Experts

1.	Frey, Aline: 10 articles (01/2011 - 10/2002)
2.	Kobrin, Isaac: 10 articles (01/2011 - 10/2002)
3.	O'Connor, Christopher M: 7 articles (01/2017 - 10/2002)
4.	Teerlink, John R: 7 articles (01/2017 - 07/2003)
5.	Rainisio, Maurizio: 7 articles (01/2011 - 05/2003)
6.	Torre-Amione, Guillermo: 6 articles (01/2017 - 07/2003)
7.	Cleland, John G F: 5 articles (01/2017 - 08/2003)
8.	Cotter, Gad: 5 articles (01/2017 - 01/2003)
9.	Dingemanse, Jasper: 5 articles (05/2012 - 04/2002)
10.	Krum, Henry: 4 articles (01/2017 - 03/2003)

Related Diseases

1.	Heart Failure 12/01/2003 - "Tezosentan is a dual ET-1 receptor antagonist that has demonstrated efficacy in improving cardiac index and reducing pulmonary capillary wedge pressure in patients with acute, decompensated heart failure. " 11/07/2007 - "Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials." 08/01/2005 - "Tezosentan failed to show benefit in patients with acute heart failure in the VERITAS study. " 08/01/2005 - "Patients (343) with acute heart failure, enrolled into two prospective placebo-controlled hemodynamic studies of tezosentan, and in whom EF was available at baseline, were included. " 01/01/2005 - "Clinical studies demonstrated mixed results for tezosentan regarding its efficacy and tolerability in the management of decompensated heart failure. "
2.	Pulmonary Hypertension 12/01/2013 - "To evaluate the efficacy of tezosentan in reducing the incidence of right ventricular (RV) failure and associated mortality in patients with pre-existing pulmonary hypertension. " 12/01/2013 - "Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial." 01/01/2004 - "Tezosentan treatment markedly attenuated the pulmonary hypertension, with a 32% decrease in MPAP (from 23 +/- 2 mm Hg to 15 +/- 2 mm Hg; P<.01) and a 22% decrease in PVR (from 860 +/- 105 dyn.s.cm(-5) to 670 +/- 96 dyn.s.cm(-5); P<.01) at the end of study. " 06/01/2012 - "Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension." 10/01/2009 - "Despite similar effects on pulmonary hypertension systemic treatment resulted in significantly higher plasma levels of ET-1 (twofold) and tezosentan (10- to 100-fold). "
3.	Lung Injury 05/01/2009 - "The results of this study indicate that tezosentan attenuates lung injury induced by aortic IR in rats. " 02/01/2012 - "Therefore, tezosentan may attenuate lung injury. " 05/01/2009 - "Histological evaluation showed that tezosentan attenuated the morphological changes associated with lung injury. " 01/01/2004 - "Thus, dual-ET receptor antagonists such as Tezosentan may be useful in the management of acute pulmonary arterial hypertension, complicating the course of OA-induced lung injury." 05/01/2009 - "The purpose of this study was to examine the effect of tezosentan on lung injury induced by abdominal aortic ischemia-reperfusion (IR) in rats. "
4.	Pulmonary Arterial Hypertension 01/01/2004 - "Thus, dual-ET receptor antagonists such as Tezosentan may be useful in the management of acute pulmonary arterial hypertension, complicating the course of OA-induced lung injury." 01/01/2006 - "Tezosentan improved survival and decreased pulmonary artery pressure in a porcine model of acute pulmonary arterial hypertension after meconium aspiration. " 01/01/2006 - "Tezosentan has the potential for effective pharmacological treatment of pulmonary arterial hypertension following acute lung injury." 06/11/2023 - "Tezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. " 01/01/2004 - "The objective of this study was to evaluate the cardiopulmonary effects of a dual-endothelin (ET) receptor antagonist, Tezosentan, on oleic acid (OA)-induced acute lung injury with pulmonary arterial hypertension in dogs. "
5.	Dyspnea (Shortness of Breath) 07/02/2003 - "A tendency for an improved dyspnea score and a decreased risk of clinical worsening was observed after 24 h of treatment with each tezosentan dose. " 11/07/2007 - "Tezosentan did not improve dyspnea more than placebo in either trial, with a mean treatment difference of -12 (95% confidence interval [CI], -105 to 81) mm . " 08/01/2004 - "Included were 130 patients hospitalized due to AHF with dyspnea at rest, despite initial treatment, and were in need of hemodynamic monitoring with cardiac index (CI)<2.5 l/min/m(2) and wedge pressure > or = 20 mm Hg. Patients were randomized in a double-blind fashion to receive placebo or tezosentan: 0.2, 1, 5, or 25 mg/h for 24 h. " 01/01/2006 - "Tezosentan, an endothelin antagonist, was tested in the biggest AHF trial ever, which, however, was terminated prematurely because it was futile to proceed given the endpoints dyspnea and death. "

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	Endothelin Receptors (Endothelin Receptor)
3.	Endothelins (Endothelin)
4.	Endothelin-1 (Endothelin 1)
5.	Endotoxins
6.	alpha-naphthyl thiourea (ANTU)
7.	Troponin I
8.	Tolvaptan
9.	Simendan (Levosimendan)
10.	Antidiuretic Hormone Receptor Antagonists

Related Therapies and Procedures

1.	Therapeutics
2.	Patient Readmission
3.	Intravenous Injections
4.	Intravenous Infusions
5.	Laparotomy